Zipalertinib

A tyrosine kinase inhibitor used in cancer treatment

Zipalertinib
[[File: Chemical structure of Zipalertinib |frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Zipalertinib is a tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is designed to target specific mutations in cancer cells, thereby inhibiting their growth and proliferation.

Mechanism of Action

Zipalertinib functions by selectively inhibiting the activity of certain tyrosine kinases, which are enzymes involved in the signaling pathways that regulate cell division and survival. By blocking these enzymes, zipalertinib can prevent the growth of cancer cells that rely on these pathways for proliferation.

Clinical Development

Zipalertinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with different types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors. These trials aim to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.

Pharmacokinetics

The pharmacokinetic profile of zipalertinib includes its absorption, distribution, metabolism, and excretion. Understanding these parameters is crucial for determining the appropriate dosing schedule and for predicting potential drug interactions.

Potential Side Effects

As with other tyrosine kinase inhibitors, zipalertinib may cause a range of side effects. Commonly reported adverse effects include fatigue, nausea, and diarrhea. More serious side effects may include cardiotoxicity and hepatotoxicity, which require careful monitoring during treatment.

Research and Future Directions

Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from zipalertinib therapy. Additionally, studies are exploring the combination of zipalertinib with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms.

Related Pages

• Tyrosine kinase inhibitor
• Cancer treatment
• Non-small cell lung cancer